Abraxis seeks to reacquire US Abraxane marketing rights from AZ
USA-based Abraxis BioScience has entered into an agreement with Anglo-Swedish drug major AstraZeneca, under which, subject to approval by the board of directors of Abraxis, the company would re-acquire the exclusive rights to market Abraxane (paclitaxel protein-bound particles for injectable suspension) in the USA. Company chief executive Patrick Soon-Shiong said pivotal trials of the agent in several new indications are scheduled to begin next year. The drug is currently approved as a treatment for metastatic breast cancer. The board of Abraxis' parent company is still considering the move, but if it decides to go ahead it will have to pay AZ a $268.0-million fee on March 31, 2009. If board approval is, not obtained then the co-promotion agreement between the two companies will remain in place but with an amended commission to AZ of 50%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze